Proffered Paper - GI, non colorectal
LINK to STREAM (needs an ESMO registration)
981O - Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): A randomised phase III trial
The abstract concludes: HAIC with FOLFOX significantly improved OS compared with TACE in patients with unresectable HCC.
Read also ESMO's Daily Reporter News:
LBA65 - The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
The abstract concludes: The addition of dual immune checkpoint inhibitors to Gem and Nab-P did not result in a significant improvement in OS, PFS, or ORR. There is a trend to improved DCR. Correlative analyses to assess biomarkers that may predict immune sensitivity in this setting are underway.
- Daniel John Renouf et al. The Canadian Cancer Trials Group PA.7 trial: Results from the safety run in of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D), and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).
1525O - The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry
The abstract concludes: QoliXane is the largest study on QoL in mPC and shows that time to deterioration of QoL is short, reflecting the aggressive nature of mPC. Nevertheless, a relevant group of mPC in 1st line have improved or maintained QoL after 3 and 6 months, indicating that QoL is a predictor of pts outcome.
- Salah-Eddin Al-Batran et al. Real-life results from the prospective QoliXane trial of the platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry.
Biliary tract cancer
The abstract concludes:
After 28 months of follow-up, bintrafusp alfa continues to demonstrate manageable safety with durable, long-lasting responses and long-term survival in this expansion cohort of Asian patients with pretreated BTC
• As of the October 24, 2019 data cutoff, 8 patients out of 30 were still alive, with 3 remaining on treatment
• No additional safety signals or deaths were observed since the initial analysis; 1 new grade ≥3 TRAE (grade 3 keratoacanthoma) was observed
• Bintrafusp alfa showed a 20% response rate with a long duration of response; 42.8% of the patients have an ongoing response after 18 months (18+, 23.5+, and 24+ months)
• The median OS was 12.7 months; 24-month OS and PFS rates were 27.7% and 11.1%, respectively
• The efficacy of bintrafusp alfa in patients with pretreated BTC compares favorably with that of mFOLFOX from the ABC-06 study (ORR, 5%; median OS, 6.2 months)2
• Bintrafusp alfa is under further investigation as a 1L (NCT04066491) and 2L (NCT03833661) treatment option for patients with locally advanced/ metastatic BTC